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Abstract
Background: Since a substantial percentage of ovarian cancers express gonadotropin receptors and are responsive
to the relatively high concentrations of pituitary gonadotropins during the postmenopausal years, it has been
suggested that receptor activation may contribute to the etiology and/or progression of the neoplasm. The goal of
the present study was to develop a cell model to determine the impact of luteinizing hormone (LH) receptor (LHR)
expression and LH-mediated LHR activation on gene expression and thus obtain insights into the mechanism of
gonadotropin action on ovarian surface epithelial (OSE) carcinoma cells.
Methods: The human ovarian cancer cell line, SKOV-3, was stably transfected to express functional LHR and
incubated with LH for various periods of time (0-20 hours). Transcriptomic profiling was performed on these cells
to identify LHR expression/activation-dependent changes in gene expression levels and pathways by microarray
and qRT-PCR analyses.
Results: Through comparative analysis on the LHR-transfected SKOV-3 cells exposed to LH, we observed the
differential expression of 1,783 genes in response to LH treatment, among which five significant families were
enriched, including those of growth factors, translation regulators, transporters, G-protein coupled receptors, and
ligand-dependent nuclear receptors. The most highly induced early and intermediate responses were found to
occupy a network impacting transcriptional regulation, cell growth, apoptosis, and multiple signaling transductions,
giving indications of LH-induced apoptosis and cell growth inhibition through the significant changes in, for
example, tumor necrosis factor, Jun and many others, supportive of the observed cell growth reduction in in vitro
assays. However, other observations, e.g. the substantial up-regulation of the genes encoding the endothelin-1
subtype A receptor, stromal cell-derived factor 1, and insulin-like growth factor II, all of which are potential
therapeutic targets, may reflect a positive mediation of ovarian cancer growth.
Conclusion: Overall, the present study elucidates the extensive transcriptomic changes of ovarian cancer cells in
response to LH receptor activation, which provides a comprehensive and objective assessment for determining
new cancer therapies and potential serum markers, of which over 100 are suggested.
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Ovarian cancer is the most lethal form of gynecological
cancer. In 2009, over 21,550 new cases were diagnosed
in the United States, and 14,600 of those cases resulted
in death [1]. The relatively high death rate, compared to
diagnosed cases, is due to the lack of an effective
method for early detection. In most cases, the cancer
has progressed to an advanced stage when detected,
with only about a fourth of the women having the dis-
ease correctly diagnosed in a localized state. As a result,
the five-year survival rate is roughly 30-40% of the diag-
nosed cases, independent of the therapies used [2].
Major factors, including inherited mutations in the
BRCA1 and BRCA2 genes [3,4] and conditions that lead
to more ovulatory periods, such as early menarche, late
menopause, and nulliparity [5], have been strongly
linked to increased risk of ovarian cancer development;
however, the role of carcinogens and other possible con-
tributing factors are still largely unknown [6].
It has been recognized for several years that a strong
correlation exists between the risk of developing ovarian
cancer and conditions such as infertility and menopause
[7-9], which lead to increased exposure to the pituitary
hormones, luteinizing hormone (LH) and follicle-stimu-
lating hormone (FSH), thus targeting the gonadotropins
as putative choices when investigating new therapy
options, a topic that has been reviewed [6,10]. Through
their regulation of granulosa, theca, and luteal cell func-
tion and differentiation, LH and FSH actions are critical
for ovarian steroidogenesis, and LH is responsible for
inducing ovulation [11-13]. As of now, there is only
indirect evidence indicating a causal relationship of
gonadotropic action and ovarian cancer development,
such as a significant number of cancer cases presenting
with LH receptor (LHR) expression and the increased
cancer risk associated with elevated gonadotropins in
serum or hypersecretion of LH [14]; the controversy still
exists whether there is a direct effect of LH on ovarian
surface epithelium (OSE) tumor growth, survival, and
progression [2,6,10,15].
In contrast to the above considerations, there are clin-
ical reports showing that the use of gonadotropins to
treat infertility does not increase the risk of ovarian can-
cer, or, if so, the risk is very slight [16,17]. This contro-
versial area, including the impact of gonadotropin
ablation with GnRH analogs, was recently reviewed with
the conclusion that if gonadotropins are involved in
ovarian cancer, their role is probably more important in
tumorigenesis and early growth, not in later stages [15].
Consistent with the clinical controversy surrounding
gonadotropins and ovarian cancer, there are mixed,
often conflicting, reports on established ovarian cancer
cell lines regarding the actions of gonadotropins on cell
proliferation, invasion, and migration [6]. Indeed, as dis-
cussed later, opposing conclusions have been reached by
different groups investigating the same cell line. Conse-
quently, a thorough examination of LH action on
genetic alteration in ovarian cancer is desired in order
to determine if LH contributes to any essential compo-
nent of cancer development such as self-sufficiency in
growth signals, evasion of apoptosis, sustained angiogen-
esis, tissue invasion and metastasis, etc. [18].
The goal of the present study was to ascertain if tran-
scriptomic profiling of an ovarian cancer cell line could
provide useful information on LH activation of LHR,
not whether LH has any role in cancer initiation. Cul-
tured SKOV-3 human ovarian carcinoma cells were cho-
sen as control (LHR-)[14,19], and the experimental cells
were obtained by stably transfecting the SKOV-3 cells to
express about 12,000 functional LH receptors per cell
(LHR+). Since we have reported elsewhere that, in in
vitro assays [20], the LHR+ cells, but not the LHR- cells,
exhibited reduced proliferation and reduced migratory
and invasive properties in response to LH, the hypoth-
esis to be tested herein is that microarray analysis can
elucidate the cellular pathways that are operative in
response to LH activation of LHR in these ovarian carci-
noma cells, by conducting a detailed examination of the
transcriptional alterations in these cells in terms of
mRNA expression and functional and pathway enrich-
ment. The results of this study have enabled us to deter-
mine the overall effects on the major pathways in the
LHR+ cells and thus obtain a better understanding of
LHR expression and LH-mediated LHR activation on
this epithelial ovarian carcinoma cell line. In addition,
over 100 proteins have been identified that warrant
further studies on their potential as serum markers of
LHR-positive ovarian cancer in postmenopausal women.
Methods
SKOV-3 Cells and Transfection
The parent SKOV-3 ovarian cancer cell line was chosen
as a control in this study since it does not express LHR
[14,19,20], and, following transfection, the LHR+ cells
serve to determine the alterations in gene expression eli-
c i t e db yL H .T h eL H R +c e l l sb o u n d[
125I]-human chor-
ionic gonadotropin with a Kd of 0.3 nM (human
chorionic gonadotropin and LH utilize the same G pro-
tein-coupled receptor, LHR), consistent with the binding
affinity using ovarian reproductive cells, and responded
to LH with increased intracellular levels of cAMP and
inositol phosphates. In total, six groups of SKOV-3 cells
(LHR-, LHR+, and LHR+ incubated with LH for various
times: 1, 4, 8, and 20 h), each with three independent
replicates, were used for examining the cell response.
These times were chosen to provide temporal
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response genes altered by LH-mediated LHR activation.
Microarray and PCR Experiments
Total RNA was extracted from the above 18 SKOV-3
samples [20] and was amplified using the NuGEN™
Ovation™ RNA Amplification System V2. The resultant
fragmented and labeled cDNA was added to the hybridi-
zation cocktail in accordance with the NuGEN guide-
lines for hybridization onto Affymetrix human genome
U133 Plus2 Arrays. Following hybridization for 18 h at
45°C, the array was washed and stained on the Gene-
Chip
® Fluidics Station 450 using the appropriate fluidics
script, before being inserted into the Affymetrix autoloa-
der carousel and scanned using the GeneChip
® Scanner
3000. The microarray analyses were done by Almac
Diagnostics, Durham, NC. The raw data has been
deposited to GEO database (Accession ID: GSE27328).
Poly(A)+ RNA was extracted from the cells and
equivalent amounts were converted to cDNA, which
was then analyzed by qRT-PCR. 23 genes are tested,
which are mostly associated with cell growth and inva-
sion (Additional file 1 Table S1). The amounts of cDNA
for each gene were determined in duplicate by qRT-
PCR with the SYBR Green detection system, and the
relative gene expression was calculated from the Ct
values, where Ct is the cycle at which the threshold (i.e.
the number of cycles at which the earliest measurable
fluorescence signal reaches 25X baseline) can be
detected in a qRT-PCR assay [21]. The relative gene
expression is given as a ratio of Ct of the gene of inter-
est to that of the housekeeping gene, GAPDH, taken as
a reference gene [GAPDH-287F: GAAATCCCATC
ACCATCTTCC
AG; GAPDH-599R: CTTTGGTATCGTGGAAG-
GACTCAT] and distilled water as a negative control,
Data Quality Control (QC) and Statistical Analyses
QC was performed for each hybridized array by asses-
sing quality metrics comprehensively, and hierarchical
clustering and principal components analysis were
employed for data QC assessment by using 26,821 tran-
scripts that passed the background filter, i.e., three times
the standard deviation of the average background inten-
sity of the 18 samples, as shown in Additional file 2 Fig.
S1. The results of clustering and data reduction were
assessed comprehensively to ascertain the suitability of
the results for further analysis.
Subsequently, statistical analyses were performed to
identify the differentially expressed genes between any
two groups, especially at the transition points when
LHR and LH are introduced. The ANOVA [22] and
Mann-Whitney tests were initially applied, and the geo-
metric mean of gene expression was calculated within
the triple duplicates. Given the different tests underlying
the individual significance, differential expression was
assessed by applying p-value < 0.05 (restraining FDR <
0.1) and fold-change ≥ 2.0. More rigorously, we only
focused on those expression changes consistently
observed at the transition points, which means the
expression levels of the triplicate measures of group A
are all higher (or lower) than those of group B. Overall,
the experimental design, coupled with the statistical sig-
nificance and fold change criteria employed, engender
high confidence of selecting reliable differential expres-
sions. Both hierarchical clustering [23] and self organiza-
tion maps (SOMs) [24] were applied to extract co-
expression patterns associated with LHR expression and
LH-mediated activation, especially to identify the signifi-
cant functional clusters among the profiles. Enrichment
analyses on functional families and pathways have been
carried out according to Gene Ontology (GO) and
KEGG curation [25], respectively.
Public Microarray Data for Normal Human Ovarian
Surface Epithelium (HOSE) Cells
Public normal HOSE expression dataset (GSE14001)
[26] was downloaded from the GEO database for com-
parative purposes, which were collected using the identi-
cal Affymetrix platform. The microarray analysis was
d o n eo nR N Ao b t a i n e df r o ms h o r t - t e r mc u l t u r e so f
three different normal human ovarian surface epithelial
cells that were initiated from the surface scraping of
normal ovaries [26]. The same RMA algorithm was
applied for gene expression summarization; no further
normalization was conducted between different cell
types to retain the variance of overall mRNA expression.
Results
In earlier in vitro studies [20], it was shown that, when
compared to LHR- cells, LHR expression, in the absence
of added LH, had no effect on cell proliferation,
although it did reduce the invasiveness when measured
using Matrigel to mimic the basement membrane;
moreover, the degree of wound closure, a measure of
migration using a scratch assay, was increased by 0.5%
fetal bovine serum in the LHR+ cells. The addition of
LH to the LHR+ cells, but not the LHR- cells, reduced
the growth rate and migratory properties, but there was
no further reduction in the invasive index compared to
that elicited by LHR alone. Herein, we examined the
corresponding gene expression changes, with one of the
goals to identify mRNA expression patterns that are cor-
related with the altered cell characteristics.
Altered Gene Expression and Coexpression Patterns
A total of 54,671 transcripts were originally profiled,
among which 2,373 genes exhibited at least 2-fold
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groups (see detailed statistics in Additional file 1 Table
S2), including 1,783 genes differentially expressed in
LH-treated cells. Out of the 23 differentially expressed
genes analyzed by qRT-PCR in this study and earlier
[20], we found that 22 genes exhibit consistent expres-
sion pattern between microarray and qRT-PCR data
(Additional file 1 Table S1), which indicate that majority
differential information derived from microarray is reli-
able. According to the IPA annotation [27], 689 differ-
ential genes are cancer-related, and 265 genes are highly
expressed in the ovary (see Additional file 1 Table S3).
Five major functional families were found to be signifi-
cantly enriched by the differentially expressed genes,
including growth factors, translation regulators, trans-
porters, G-protein coupled receptors, and ligand-depen-
dent nuclear receptors (Figure 1). Generally, these
differentially expressed genes participate in pathways
involved in the cell cycle, focal adhesion, cytokine-cyto-
kine receptor interaction, regulation of the actin cytos-
keleton, purine metabolism, and a number of key
signaling pathways such as MAPK, TGF-b, p53, and
Jak-STAT.
The 2,373 genes were subject to hierarchical clustering
[23] for identification of distinct gene-expression pat-
terns across all sample groups. In Figure 2A, different
expression patterns were observed across the five differ-
ent transitions, i.e. LHR-/LHR+ and LHR+/LHR+ plus
LH for each of the four time points, clearly supporting
the hypothesis that LHR expression and LH-mediated
receptor activation impose significant effects on gene
expression in ovarian cancer cells.
In total, 12 highly correlated expression patterns were
identified from the differentially expressed genes, by
using a self organization map (SOM) [24] (Table 1). The
gene lists of each cluster are given in Additional file 1
Table S4. Seven clusters (C1-C7) represent the up-
regulated genes, while the other five show down-regu-
lated genes concomitant with LHR expression in the
cells. After incubation of LH with the LHR+ cells, the
genes of each group became more diverse in terms of
their expression level changes, either being up-regulated,
down-regulated, or unchanged, falling into five cate-
gories. Within each cluster, enriched GO and pathways
were identified (Table 1), reflecting the major involved
functional groups or cellular processes, as discussed in
the next two sections.
Genes regulated by the Presence of LHR and Relevant
Pathways
Of the 414 genes that were differentially expressed sig-
nificantly when LHR was introduced, 144 were up-regu-
lated and 270 down-regulated. A few pathways,
including gap junction, purine metabolism, calcium sig-
naling, and actin cytoskeleton regulation, are associated
with the up-regulated genes, perhaps indicating a mod-
erate activation of these processes. Since one of the
objectives is to examine the regulation of the genes that
may promote or inhibit tumor growth, migration, and
invasiveness in LHR+ tumors, the up-regulated
TUBAL3, TUBB2B,a n dGUCY1B3 genes involved in
gap junction formation and function may indicate a
reduced tumor progression and metastasis [28]. Oppos-
ing these increased expressions, LHR+ cells exhibit sig-
nificant down-regulation of genes associated with
cellular processes such as cell communication, ECM-
receptor interaction, regulation of vesicle fusion, and
focal adhesion, for example genes encoding extracellular
matrix structural constituents (KRT7, DSC3, KRT16,
TNC, LAMB3), collagens (COL3A1, COL6A3, COL4A1,
COL1A2), and matrix metalloproteinases (MMP1,
MMP2, MMP13, MMP14). The negative effect on cell
communication and ECM interaction is consistent with
a reduced invasive activity of the cancer cells, thus
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Figure 1 Distributions of the 2,373 differentially expressed genes in SKOV-3 cells across IPA functional families.E a c hb l u eb a r
represents the percentage of differentially expressed genes associated with LHR expression; each yellow bar represents the percentage of
differentially expressed genes upon incubation with LH; each red bar is the percentage of all human genes. The x-axis represents the percentage
and the y-axis denotes functional families.
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Page 4 of 16inhibiting cancer progression. In addition, other down-
regulated genes are found relevant to apoptosis (PIK3R3,
IL1R1, FAS, TNFSF10) and major signaling pathways
(P53, TGF-b, ERBB HER-2).
Responses of Gene Expression and Pathways Following
LH-Mediated LHR Activation
A total of 1,783 genes were found to be regulated by
LH, when compared to gene expression in LHR+ cells
(including all clusters in Table 1 except for C4 and
C10). The up-regulated genes are enriched in 21 path-
ways (Table 2), including VEGF signaling, gap junction,
and immune responses (the Toll-like receptor signaling
and the B cell receptor signaling pathways). Besides the
immune responses that are generally observed in most
types of cancers, the activation of genes involved in
VEGF signaling may be hypoxia responsive and intro-
duce a positive effect on cancer growth, while those
involved in gap junction and Notch signaling accelerate
cell-cell communication and influence several key
aspects of the normal development by regulating differ-
entiation, proliferation, and apoptosis [29].
The genes that are down-regulated by LH represent
22 pathways (Table 2). Besides the continuous inhibition
of the cell cycle, p53 signaling, and the complement and
coagulation cascades, LH also seems to impose a nega-
tive and delayed effect on a few metabolic pathways
related to pyrimidine, glycerolipid, methionine,
androgen, and estrogen metabolism. These results indi-
cate an LH-mediated reduction in certain aspects of
nucleic acid, lipid, and amino acid metabolism. Since
the epithelial cells are not steroidogenic, the down-regu-
lation of androgen and estrogen pathways may relate
more to sex steroid action [30,31].
Table 2 shows 34 additional pathways consisting of
both up- and down-regulated genes to different extents,
among which the overall effects on tumor growth and
apoptosis cannot be evidently inferred. For a few, one
particularly interesting observation is the substantially
increased expression of the tumor necrosis factor mem-
ber 10 gene (TNFSF10), involved in natural killer cell-
mediated cytotoxicity (Figure 3). TNFSF10 encodes the
cytokine tumor necrosis factor-related apoptosis-indu-
cing ligand (TRAIL) that binds to TNF and induces
apoptosis, primarily in tumor cells [32].
Genes Most Highly-Expressed and Most Differentially-
Expressed
To exclude the possibility that some effects of LH on cell
growth and apoptosis were masked by the extremely high
levels of gene expression in SKOV-3 cells, the most
highly-expressed genes (top 5%, ~3000 transcripts) in each
group were examined and compared with those from nor-
mal HOSE cells. Figure 4 shows that the genes most highly
expressed in SKOV-3 cells and normal HOSE cells are lar-
gely different, with only 1,726 out of the 3,000 transcripts
A     B  FC
Figure 2 A. A heatmap showing normalized gene-expression profiles for SKOV-3 cells under six conditions. B. A heatmap showing
gene-expression patterns under different regulation (for each group, the mean expression value of the three replicates is shown, and the five
transitions are LHR+/LHR-, LH1/LHR+, LH4/LHR+, LH8/LHR+ and LH20/LHR+), where LHR- denotes the control or mock-transfected SKOV-3 cells,
and all others are the LHR+ cells with no LH added or after incubation with LH for 1, 4, 8, and 20 h, respectively.
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Page 5 of 16Table 1 12 gene clusters identified from the differentially expressed genes
Categories Clusters
LHR-,LHR+,1h,4h,8h, 20h
#. of genes GO(s) enriched Pathways enriched
1
144 extracellular matrix structural constituent
platelet-derived growth factor alpha-receptor activity
regulation of vesicle fusion
hydroxyacid-oxoacid transhydrogenase activity
TCR
EGFR1
LH(↑)/LHR(↑)
2
157 negative regulation of apoptosis
leukocyte differentiation
carboxylic acid metabolic process
EGFR1
TGFBR
ID
KitReceptor
3
152 multicellular organismal development
cell proliferation
cyclic-nucleotide phosphodiesterase activity
regulation of transcription, DNA-dependent
cell-cell signaling
Hematopoietic cell lineage
LH(-)/LHR(↑)
4
205 nervous system development
neurogenesis
notch binding
calcium ion binding
cell morphogenesis
NOTCH
5
157 response to external stimulus
positive regulation of cellular metabolic process
AndrogenReceptor
EGFR1
LH(↓)/LHR(↑)
6
270 cadmium ion binding
transcription
spermidine biosynthetic process
regulation of RNA metabolic process
MT-HeavyMetal-Pathway
TCR
IL4
TNF alpha/NF-kB
7
167 neutrophil chemotaxis
positive regulation of heart rate
calcium-mediated signaling
leukocyte chemotaxis
regulation of cell migration
IL-7
ID
LH(↑)/LHR(↓)
8
145 extracellular region
collagen fibril organization
complement component C3b binding
fibrillar collagen
inflammatory response
response to external stimulus
protein digestion
IL-7
Wnt
9
261 amylase activity
calcium ion binding
homophilic cell adhesion
synaptogenesis
IL-7
EGFR1
LH(-)/LHR(↓)
10
288 proteinaceous extracellular matrix
polysaccharide binding
glycosaminoglycan binding
regulation of defense response
G-protein signaling, coupled to IP3 second messenger
enzyme inhibitor activity
Wnt
EGFR1
LH(↓)/LHR(↓)
11
71 regulation of aldosterone metabolic process
regulation of hormone metabolic process
auditory receptor cell differentiation
epidermis development
growth factor activity
NOTCH
TGFBR
12
191 cell cycle phase
mitosis
microtubule cytoskeleton
BCR
Plots in the 2nd column represent the expression pattern of six conditions (SKOV-3 control, i.e. mock-transfected (LHR-), LHR expression but with no added LH,
and incubation of the LHR+ cells with LH for 1h, 4h, 8h, and 20h) “↑” and “↓” denote responses of up-regulation and down-regulation, respectively and “-”
denotes no alteration of gene expression.
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Page 6 of 16Table 2 Pathways significantly enriched by differentially expressed genes regulated by LH (p-value < 0.5)
21 pathways uniquely involved in the up-regulated genes
Pathway (up-regulated genes involved) LHR+ LH1 LH4 LH8 LH20
Gap junction 3 5
Melanogenesis 3 5 4 5
Toll-like receptor signaling pathway 3 8
Epithelial cell signaling in Helicobacter pylori infection 3 4 3
VEGF signaling pathway 44
Adherens junction 53 3
B cell receptor signaling pathway 3 6
Adipocytokine signaling pathway 3 4
Hedgehog signaling pathway 3
Basal cell carcinoma 3
Cell adhesion molecules (CAMs) 3
Long-term potentiation 3
Glutathione metabolism 5
Long-term depression 4
Androgen and estrogen metabolism 4
Dorso-ventral axis formation 3
mTOR signaling pathway 3
Metabolism of xenobiotics by cytochrome P450 5
Arachidonic acid metabolism 3
Fc epsilon RI signaling pathway 6
GnRH signaling pathway 3
22 pathways uniquely involved in the down-regulated genes
Pathway (down-regulated genes involved) LHR+ LH1 LH4 LH8 LH20
Cell cycle 3 11 3 14
p53 signaling pathway 3 10
Complement and coagulation cascades 7 4
Pyrimidine metabolism 8
Alanine and aspartate metabolism 5
Urea cycle and metabolism of amino groups 6
Valine, leucine and isoleucine degradation 4
Propanoate metabolism 3
Neurodegenerative Diseases 3
Pyruvate metabolism 3
Alkaloid biosynthesis II 3
Glycerolipid metabolism 3
Carbon fixation 3
SNARE interactions in vesicular transport 3
beta-Alanine metabolism 4
Arginine and proline metabolism 4
Methionine metabolism 3
Selenoamino acid metabolism 3
Aminoacyl-tRNA biosynthesis 4
Phenylalanine metabolism 5
Glutamate metabolism 3
Basal transcription factors 3
34 pathways involved in both up- and down-regulated genes
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Pathway (both up-/down-regulated genes involved) LHR+ LH1 LH4 LH8 LH20
MAPK signaling pathway 4 8 9 6 15
3 3 12
Apoptosis 7
4 6
Focal adhesion 3 6 4 21
12 9
Regulation of actin cytoskeleton 3 3 5 16
3 3 7
TGF-beta signaling pathway 4 7 4 7
3 4
Cell Communication 11
13
ECM-receptor interaction 15
10
Jak-STAT signaling pathway 4 6 8
3 4
Tight junction 34
4
ErbB signaling pathway 35
4 4
Wnt signaling pathway 4
7
PPAR signaling pathway 3
3
Purine metabolism 3 3 3 4
8
Cytokine-cytokine receptor interaction 9 13 5 12
8 3 8
Axon guidance 631 1
4 6
Prostate cancer 3 5 3 8
5
Hematopoietic cell lineage 56 7
3
Natural killer cell mediated cytotoxicity 4 6
4
Neuroactive ligand-receptor interaction 3 3
6 3
Calcium signaling pathway 3 3 6
4 7
Insulin signaling pathway 45
6
Glycerophospholipid metabolism 4 5
3
Complement and coagulation cascades 3 7
7 4
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Page 8 of 16in common. The 1,056 unique genes, specific in the LHR-
SKOV-3 cells, are participating in the regulation of trans-
lation, cell division, chromosome partitioning, post-trans-
lational modifications, protein turnover, chaperones, and
signal transduction mechanisms, indicating possible altera-
tions of these processes in cancer compared to normal
HOSE cells, such as an increase in the overall rate of pro-
tein synthesis and translational activation of the mRNA
molecules involved in cell growth and proliferation. The
majority (2,748) of the highly expressed genes in the LHR-
SKOV-3 cells continue to be expressed in the LHR+ cells.
In contrast, the highly-expressed genes are quite con-
sistent in the LHR+ cells incubated with LH, where
3,560 genes were involved. The 689 genes specifically
introduced by LH-mediated LHR activation, compared
to LHR+ cells, reveal the involved cellular processes
such as coenzyme metabolism, post-translational modifi-
cations, nucleotide transport, DNA replication and
repair, intracellular trafficking, and secretion.
In addition, the most differentially expressed genes
were examined (Additional file 1 Table S5), and a few
were found to be altered significantly by LHR expres-
sion, such as ERBB4 (↓46) and CASP1 (↓44). Down-reg-
ulation of ERBB4 is deemed to be beneficial as its over-
expression may promote cell proliferation, while down-
regulation of CASP1 may result in a suppressive effect
on cell apoptosis [33]. Following LH activation of LHR,
t h em o s th i g h l yu p - r e g u l a t e dg e n e s ,e . g . ,PDE4B,
TNFSF10, FOSB, and the highly induced early and inter-
mediate response genes, e.g., THBS1, CCl20, DUSP1, are
found to occupy a gene network connecting transcrip-
tional regulation, cell proliferation and differentiation,
apoptosis, and multiple signaling transductions such as
MAPK, Erk1/Erk2 MAPK, Jak-STAT, VEGF, and the
TGF-b signaling pathway. Thus, from some of the
results one could argue that LH may serve as a positive
regulator on cancer growth and invasion through over-
expression of CCl2 and FOSB. However, the large
increase in the expression of TNFSF10 can act to
increase apoptosis. The high level of up-regulation of
PDE4B is interesting since the enzyme, a cyclic nucleo-
tide phosphodiesterase up-regulated by cAMP [34], is
responsible for inactivating cAMP and thus rendering
the cells refractory to additional LH signaling for an
extended time.
Major Pathways Altered in the LHR+ and LH+ SKOV3
Cells
Ovarian carcinogenesis is a complicated process that
involves the deregulation of multiple signaling
Table 2 Pathways significantly enriched by differentially expressed genes regulated by LH (p-value < 0.5) (Continued)
Tryptophan metabolism 35
4
T cell receptor signaling pathway 3 6
3
Starch and sucrose metabolism 3
4 3
Leukocyte transendothelial migration 11
5 4
Nitrogen metabolism 6
3
Phosphatidylinositol signaling system 3
3
Tyrosine metabolism 3
6
Histidine metabolism 3
4
Ubiquitin mediated proteolysis 3
9
Glycan structures - biosynthesis 1 3
3 4
Glycine, serine and threonine metabolism 3
6
The number in each cell represents the number of differential genes involved in the corresponding pathway. (Note: the top areas designate up-regulated genes,
while the underlined (bold) one (bottom) signify down-regulated genes.)
Cui et al. BMC Cancer 2011, 11:280
http://www.biomedcentral.com/1471-2407/11/280
Page 9 of 16pathways. In this study, proteins and signaling path-
ways involving Wnt signaling, p53 tumor suppressor,
APC/b-catenin signaling, K-Ras concogene, and EGFR
tyrosine kinase were found to be affected by LH activa-
tion of LHR, either positively or negatively. Of particu-
lar interest was the result demonstrating that LH
dramatically activates the expression of the interleukin-
6g e n e( IL-6)( 3 3 ↑), a pleiotropic cytokine that is
assumed to be involved in ovarian carcinogenesis and
may induce signaling pathways such as toll-like recep-
tor, NOD-like receptor, cytosolic DNA-sensing, and
Jak-STAT [35,36], which, in this sense, may indicate a
potential therapeutic target for treating ovarian cancer.
Moreover, an increase in the production of potent
growth factors like IL-8 may facilitate tumor growth
and angiogenesis [37].
To sum up the major impact of LH, we have grouped
all involved pathways (Additional file 1 Tables S6-7)
according to their cellular functions (Table 3). A few of
them were selected for a closer examination (cf. Discus-
sion), which include the cell cycle, the MAPK pathway,
apoptosis, the Jun and Fos family of transcription fac-
tors, and other signaling pathways.
Identification of Potential Molecular Markers
A comparison of the gene expression profiles between
n o r m a lO S Ec e l la n dS K O V - 3c e l l s( i n c l u d i n ga l lL H R +
cancer cells) has the potential to identify a group of
genes that can discriminate between normal and cancer
cells regardless of LHR expression and LH action. Two
lists of genes have been identified as up-regulated (185
genes) and down-regulated (248 genes) in all cancer ver-
sus normal cells, whose expression profiles are shown in
Figure 5 (see names in Additional file 1 Table S9). Func-
tional analysis reveals that the up-regulated genes are
involved in cell communication, ECM-receptor interac-
tion, and focal adhesion, especially functioning in cell
division and chromosome partitioning, as well as carbo-
hydrate transport and metabolism, which are fundamen-
tal processes for cancer growth. We have conducted the
specificity analyses of the identified markers against
public microarray gene-expression data for other human
diseases (http://bioinfosrv1.bmb.uga.edu/DMarker/) and
obtained 106 genes whose differential expression are
specific to ovarian cancer. Among these genes, nine
have been reported with the same expression changes in
a newly-developed YDOV-157 cell line versus HOSE
 
(Ct is normalized by calculating the ratio to that of GAPDH) 
Figure 3 qRT-PCR measures of gene TNFSF10 and ET-1. The left panel shows the normalized Ct of TNFSF10 (primer sequence (F)
AAGACTGTCAGCTTCCAAACATTAA(R) GTGATACACTACT TGAGAGATGGAT) and the right panel shows the normalized Ct of ET-1 (primer sequence
(F) AGGCCCTGAGTTGGCAGTGGCCCAT (R) ATGGGCCACTGCCAACTCAGGGCCT).
Figure 4 Venn diagram of the top 3,000 differentially expressed genes from HOSE cells, mock-transfected SKOV-3 cells (LHR-), and
LHR+ cells (LHR) (left), and temporal effects after addition of LH to the LHR+ cells (right), respectively.
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Page 10 of 16(Additional file 1 Table S9), which illustrate some con-
sistency between different cell lines. These results
engender confidence in proposing some genes as poten-
tial molecular markers to discriminate between ovarian
epithelial carcinoma cells and normal OSE cells. Based
on a recently developed approach from this laboratory
[38], 103 of these genes (Additional file 1 Table S9)
were predicted in which their protein products may be
secreted into the bloodstream, thus providing another
important pool of potential serum markers for further
investigation. According to the proteomic reports from
the Plasma Proteome Project (PPP) [39] and a literature
search for diseased protein markers [38], we know that
22 of these proteins have been identified as secreted
proteins in normal or diseased blood (Additional file 1,
Table S9). While it is unlikely that just one marker
would emerge with good specificity and sensitivity, com-
binations of two or more may prove highly useful. Some
of the predicted proteins could be peptides/fragments
derived from extracellular matrix proteins and mem-
brane receptors, many are readily soluble and assayable,
e.g. chemokine ligands 1, 5, 9, 10, 11, and 18, placental
growth factor (PGF), and growth hormone secretagogue
receptor ligand (GHRL), to mention but a few.
LH Regulation on Known Therapeutic Targets
Our literature search against the Therapeutic Target
Database (TTD) [14] found that 48 therapeutic targets
were reported to be ovarian cancer-associated, including
18, 20, and 12 targets in three categories, successful,
clinical trials and, research, respectively (detailed list in
Additional file 1, Table S10). Our data cover 39 of the
48 therapeutic targets, some of which are significantly
regulated by LHR activation. Table 4 lists four of these
targets with the greatest changes in gene expression.
Endothelin-1 (ET-1)-mediated activation of the endothe-
lin-1 receptor is known to result in vasoconstriction and
smooth muscle cell proliferation and is implicated in the
pathogenesis of hypertension, coronary vasospasms, and
heart failure. More recently, it has been shown that ET-1,
acting through its G protein-coupled receptor, ETAR, is an
important component of ovarian cancer initiation and
progression [40-42]. These findings have led to an interest
in the development of endothelin-converting enzyme-1
inhibitors and small interfering RNAs as a new therapeutic
agent for ovarian cancer [43]. Interestingly, the LHR+ cells Table 3 Number of altered pathways contributing to a
general cell function (The detailed of each pathway can
be found Additional file 1, Table S6-7)
General function Number of pathways involved
Signaling 34
Receptor interaction 3
Metabolism 31
Junctions 3
Disease 23
Immune system 19
Apoptosis 14
Cell cycle 9
Gene expression/regulation 11
Miscellaneous 41
 
Figure 5 A heatmap of the 185 and 248 genes, up-regulated
and down-regulated, respectively, in normal HOSE versus
SKOV-3 cells: control (LHR-) and LHR+ receiving no LH (LHR+)
and following incubation with LH for 1, 4, 8, and 20 h.
Table 4 Illustration of the reported therapeutic targets
that are regulated by LHR activation
Type Target name LHR
+
LH1 LH4 LH8 LH20
Research Endothelin-1 (ET-1) -1.1 10.2 4.3 1.8 2.1
Research Stromal cell-derived factor 1
(SCD-1)
1.2 1.6 10.3 6.3 4.2
Research Insulin-like growth factor II
(IGF2)
-8.7 8.6 11.6 3.9 9.2
Clinical
trail
Kinesin-like protein KIF11
(KIF11)
-1.5 -1.1 -2.3 -1.3 -1.6
Fold changes are shown; the category (successful, clinical trial or research)
indicates the different phase of the therapeutic targets discovery.
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Page 11 of 16respond to LH with a 10-fold increase in ET-1 gene
expression, peaking at 1 h and remaining slightly elevated
up to 20 h. The LH-mediated increase in ET-1 gene
expression was confirmed by qRT-PCR (Figure 3). ETAR
expression is also increased about 2-fold in response to
LH, while there are no significant effects on expression of
the genes for endothelin-converting enzyme-1 and the
endothelin B receptor. These results alone could indicate a
possible enhancement of cell proliferation in response to
LH. LH-mediated LHR activation also significantly up-reg-
ulates the stromal cell-derived factor 1 (SCD-1) and insu-
lin-like growth factor II (IGF2) genes. The former has
been reported to increase the invasiveness and migration
of breast cancer cells [44], and the latter is known as a
fetal promoter of cell proliferation that is involved in var-
ious forms of cancer [45]. The up-regulation of just these
genes could suggest that LH exerts positive effects on
tumor growth and metastasis. We know, however, from
the experimental evidence that the up-regulation asso-
ciated with these growth-promoting genes is not mani-
fested in LH-activated LHR+ cells, and thus expression of
the other negative regulators, e.g. c-JUN, TNFSF10, and
MMPs, must assume a dominant role in relating gene
expression and tumor cell properties.
Discussion
This work presents data obtained using a novel epithe-
lial carcinoma cell model for studying the response to
LHR expression and activation in ovarian cancer,
mimicking a significant percentage of tumors that arise
in postmenopausal women, i.e. characterized by LHR
expression and high circulating concentrations of LH.
Overall, the results showed dramatic changes in the
transcriptome elicited by the expression of LHR in
SKOV-3 cells with no added ligand and following addi-
tion of LH to the LHR+ human ovarian cancer cells.
The expression of LHR, in the absence of LH, altered
the transcription of 414 genes. This result could arise
from a small increase in signaling, e.g. via protein
kinases A and C, if the receptor infrequently adopts an
active conformation; there may also be some degree of
ligand-free signaling of LHR. Functional and pathway
analyses revealed both positive and negative effects of
LH-mediated LHR activation on LHR+ SKOV-3 cell
growth and apoptotic pathways. Since we know from
earlier studies that LH addition to the LHR+ SKOV-3
cells led to an inhibition of growth over a 7-day time
course and that LH acted to reduce invasion and migra-
tion in short-term in vitro assays [20], one can speculate
that the dominant transcriptomic changes leading to the
observed cellular phenotype in response to LH could
involve up-regulation of TNFSF10, TUBAL3, and
TUBB2B, as examples, and down-regulation of c-JUN
and the MMPs, again as examples.
Conflicting reports on various ovarian carcinoma cell
lines have appeared, perhaps reflecting to some extent
the heterogeneous nature of ovarian cancer as reflected
in the cell lines used [6], as well as possible further ded-
ifferentiation of the cells in long-term culture. For
example, there are several reports on SKOV-3 cells
showing the presence of LHR by Western blots and
responses to LH, including increased: cell proliferation
(at 0.1 and 1 μg/mL, but not at 10 ng/mL) and invasive-
ness, MMPs 2 and 9, cyclooxygenases 1 and 2, and
AKT, and decreased tissue inhibitor of metalloprotei-
nase-1 [46,47]. However, other reports, based on PCR,
[
125I-hCG] binding, and immunohistochemistry, failed to
detect LHR in SKOV-3 cells [14,15,20]; moreover, 0.1
μg/mL of hCG [19] and 0.5 μg/mL of LH [20] did not
lead to increased proliferation. These discrepancies are
not easily explained, other than the real possibility that
different variants exist in SKOV-3 cells, arising perhaps
from long-term culture and passage number. Hence,
each report in which the presence or absence of LHR is
documented must be based on its own merit. For the
studies reported herein, we have confidence that the
mock-transfected SKOV-3 cells used do not express
LHR, while the transfected cells express a functional
gonadotropin receptor.
To examine if the LH-mediated alteration in gene
expression is specific to SKOV-3 cells, we compared the
gene expression changes reported in other cell types
include human cumulus cells [48], granulosa lutein cells
[49], and granulosa cells [50], all modulated by LH or FSH
(Additional file 1, Table S11). Among our so-identified dif-
ferentially expressed genes that also overlap with those
reported in each of the above studies, only a small portion
of genes, say 7 (out of 21), 4 (out of 6), and 5 (out of 23),
shows consistent alteration in SKOV-3 versus other cells.
Another study reported human LH (2-4 μg/mL) and CG
(10 IU/mL) consistently evoked oscillatory calcium signals
in HEK293 cells transfected with the human LH receptor
[51]. Our findings that the moderately activated calcium-
mediated signaling pathway and the calcium ion-binding
pathway reflected by the up-regulated genes may suggest a
similar effect in SKOV-3 cells, which needs further investi-
gation. These studies suggest that LH-mediated LHR acti-
vation impacts on various types of cells, but some of the
alterations identified in the current study are more specific
to SKOV-3 cancer cells.
An analysis based on transcriptomic profiling alone is
far from adequate to accurately conclude the overall
effects of LH-mediated LHR activation on ovarian can-
cer, but this work exemplifies the gargantuan amount of
information and cellular responses associated with LHR
expression and activation in ovarian epithelial cancer
cells. The involvement of several pathways deserves
further elaboration.
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number of up-regulated connexins that are known to
function as tumor suppressors, regulating cell growth,
differentiation, and, possibly, metastasis. The most
highly expressed genes of the connexins, including
GJA1, GJA3, and GJA7, were moderately up-regulated. It
is known that cancer cells frequently exhibit down-regu-
lation of gap junction proteins [52], and chemopreventa-
tive treatments to increase connexins offer improved
anticancer activity; thus, viewed from the up-regulation
of connexin genes, LH may exhibit a moderate negative
effect on cancer growth and migratory properties. This
observation is consistent with the finding that LH
reduces the growth rate, migration, and invasiveness of
LHR+ SKOV-3 cells [20].
Apoptosis plays an important role in cancer develop-
ment and is closely associated with the cell cycle. In the
present research, 61 of the 2,373 genes of interest were
found to participate in apoptosis, and their functions
range from promoting or inhibiting the pathway. There
are minimal effects on the most apoptosis-related genes,
including P53, P21, BCL-2, BAX,a n dBAD,b u ts i g n i f i -
cant down-regulation of some other genes, such as
CACSP1, PPP1R15A, PLEKHF1, BMF TRAF3,a n dFAS,
m a yi n d i c a t eam o d e r a t ei n h i b i t i o no fa p o p t o s i s .T h i s
possibility, of course, needs further investigation. These
results complement and extend the observations of
others on LHR+ OVCAR-3 cells, in which it was shown
that LH inhibited cisplatin-induced apoptosis by increas-
ing the expression of the IGF gene but not those for
BCL-2 and BAX [53].
Natural killer cell-mediated cytotoxicity was selected
because of its involvement in cancer treatment and its
inclusion of the six differentially expressed genes such as
TNFSF10,o n eo ft h em o s th i g h l yu p - r e g u l a t e dg e n e s
observed in this study. TNFSF10 has been studied exten-
sively in relation to human cancer because of its cytotoxic
effects on tumor cells. Its encoded protein, TRAIL, can
bind to members of the TNF superfamily and induce
apoptosis. The dramatic up-regulation of TNFSF10 in the
presence of LH may indicate enhanced apoptosis. How-
ever, many transformed cell lines have also shown resis-
tance to the effects of the protein, despite expressing the
appropriate receptors [54]. Tumor cell survival may be
due, in part, to the inhibition of TRAIL activity, e.g. to the
expression of osteoprotegerin (OPG) [55]. More studies
need to be performed to infer the effectiveness of this up-
regulation on apoptosis of ovarian tumor cells. Another
oncogene, VAV3, known to regulate cell growth and
androgen receptor activity in prostate cancer [56], also
showed a significant increase with LH addition. These two
alterations strongly suggest that further studies on the LH-
induced effects of natural killer cell-mediated cytotoxicity
are warranted on ovarian cancer.
The Jun and Fos family of transcription factors are
discussed because of the observed effects that LHR
expression and LH-mediated activation had on their
g e n ee x p r e s s i o n ,a sw e l la st h e i ri n t e g r a lr o l e si nc a n c e r
development. The oncogene, c-JUN, was found to play a
role in promoting the cell cycle through stimulation of
Ras, specifically activating crucial cell-cycle regulators
and thus inducing the G1-S transition and enhancing
cancer development and progression. Other members of
the Jun family, such as JUNB and JUND,w e r ef o u n dt o
have opposing functions to that of c-JUN,a n di nm o s t
cancers are observed to exhibit decreased expression
[57]. In the present study, c-JUN expression was
decreased after 20 h of incubation with LH, while the
expression of JUNB and JUND showed only marginal
c h a n g e s .T h ei m p o r t a n c eo fJUN expression in cancer
development may indicate that its down-regulation
could provide beneficial effects in controlling cancer and
that the consequential up-regulation of a few less
important cancer-promoting genes may be tolerated in
view of the overall benefits achieved by controlling JUN.
However, highly significant changes in FOS (16↑)a n d
FOSB (61↑) after 1 h of LH treatment indicate an
enhanced regulation in cell proliferation, malignant
transformation, and invasion. It has been reported that
relatively high concentrations of LH increases prolifera-
tion and invasiveness of SKOV-3 cells [46,47], which is
somewhat surprising in view of the absence of measure-
able LHR expression in these cells [14,19,20]. An oppo-
site finding was observed in LHR+ SKOV-3 cells [20].
Again, further investigations are needed to elucidate the
overall effects of LH regulation on ovarian cancer.
The cell cycle was chosen because of its importance
in the regulation of cell proliferation, whose control
mechanisms are often altered in cancer, leading to aber-
rant cell growth [58]. In the present study, most of the
cell cycle-related genes were found to be involved at the
G1/S and G2/M transitions and were down-regulated by
LHR expression and activation. Other stages of the cell
cycle in which altered gene expression was found
include chromosome segregation, anaphase, mitotic
spindle localization, and the spindle checkpoint. The
down-regulation of cell cycle-associated genes is consis-
tent with a reduced proliferation rate in the presence of
LH.
MAPK pathways are involved in the regulation of sev-
eral physiological responses, such as cell proliferation,
apoptosis, cell differentiation, and tissue development.
Earlier studies have implicated the involvement of the
MAPK cascade in carcinogenesis after linking the con-
stitutive activity of MAPK proteins to be associated with
cell transformation [6]. Therefore, the MAPK pathway
has been considered a target pathway for cancer therapy
[59]. Our data analysis revealed that, for each transition,
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expressions, as shown in Additional file 1, Table S8.
However, it is inconclusive whether the LH effect
through the MAPK pathway is growth enhancing or
suppressing based on the gene expression data alone.
The results obtained herein and in the earlier study [20]
on the LHR+ SKOV-3 cells are consistent with reports
that hCG is protective for breast cancer [60]. Others,
working with breast cancer MCF-7 cells, provided evi-
dence that hCG decreases the proliferation and invasive-
ness of these cells by inhibiting NF-Ba n dA P - 1
activation [61]. Clearly, further studies are needed on a
variety of ovarian carcinoma cell lines and primary cells
to sort out the role of LH and hCG on cellular proper-
ties. From the data available, it seems unlikely that LH
is tumorigenic for ovarian cancer [15], but its actions in
cellular proliferation, invasiveness, and migration remain
controversial.
Ongoing and additional studies are required to enable
transcriptomic profiling to be useful as a diagnostic
technique and as a template for treatment and biomar-
ker discovery. The results presented herein represent
but one example of many showing that microarray
results alone, while providing extremely valuable infor-
mation, often gives conflicting suggestions of cellular
properties and always require functional studies to sort
out the dominant pathways. One of the major findings
of this work was the observation that > 100 proteins
may be secreted into circulation in response to LH acti-
vation of the LHR in the SKOV-3 cells. This prediction,
based on our documented approach [38,62], warrants
further investigation in a diligent effort using clinical
samples and these suggested proteins in an attempt to
discover new biomarkers for ovarian cancer.
Conclusions
Using LHR+ SKOV-3 ovarian cancer cells, our studies
have demonstrated that the presence of LHR and its
activation by LH results in differential expression of
over 2,370 genes, leading to alterations in myriad cellu-
lar pathways. Up-regulation of several genes is consis-
tent with the measured cellular responses to LH, i.e. a
reduction in proliferation and migration. Further, over
100 proteins are suggested as potential serum markers
in LHR+ ovarian neoplasms in the presence of LH, e.g.
a large majority of post-menopausal women.
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